Skip to main
CLPT

CLPT Stock Forecast & Price Target

CLPT Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

ClearPoint Neuro Inc is experiencing promising financial momentum, highlighted by a reported 17% topline growth in 2023 and a significant reduction in cash burn. The company is poised for further success in 2024, with expectations of at least 20% revenue growth driven by the expansion of its partnership base and enhanced service offerings in the Biologics sector. Additionally, the recent product approvals, record system installations, and supportive clinical publications indicate a robust foundation for sustained growth and improved profitability moving forward.

Bears say

ClearPoint Neuro Inc has demonstrated a significant decrease in cash burn, reducing it from $5.8 million in the first quarter of 2023 to $1.2 million by the fourth quarter of 2023. While the company anticipates continuing this trend into 2024, the persistently high cash burn prior to this reduction raises concerns about the overall financial stability and the efficiency of their operations. Additionally, a continued reliance on variable revenue streams inherent in medical device sales may pose challenges to sustained profitability and long-term growth potential.

CLPT has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Clearpoint Neuro Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Clearpoint Neuro Inc (CLPT) Forecast

Analysts have given CLPT a Strong Buy based on their latest research and market trends.

According to 3 analysts, CLPT has a Strong Buy consensus rating as of Dec 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $27.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $27.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Clearpoint Neuro Inc (CLPT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.